DRIVEN by the need to whittle away at the price of pharmaceuticals, the US is approving new generic drugs faster and more consistently than ever, according to a report by the Regulatory Affairs Professionals Society.
CEO of the US Food and Drug Administration Scott Gotlieb last week indicated that the agency would expand abbreviated new drug applications (ANDA) and see priority reviews, which would accelerate generic competitors to market more quickly and help bring down costs.
The years 2016 and 2017 have already seen consecutive record approval numbers.
See the FDA's Generic Drug Review Dashboard at fda.gov.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 17